VEGF Signaling Promotes Cell Growth and Metastasis in Intrahepatic Cholangiocarcinoma in a VEGF Receptor Mediated Pathway

NCT01917370 | Unknown

• 1 other identifier: k0113011-2013ICC
• Study Type: observational
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

The investigators study the VEGF signaling in ICC cell lines／human tissues and its mechanism in HCC growth, proliferation and apoptosis.

Conditions

Intrahepatic Cholangiocarcinoma

Keywords

intrahepatic cholangiocarcinoma; icc; vegf signal pathway

Outcome Measures

Primary Outcomes (1)

• the variation of the quantity of VEGF signal pathway genes in normal liver tissue,peri tumor,tumor and metastasis.

  the sections would be collected as previously described.Western blot,immunohistochemistry,PCR would be conducted to find out the variation between the normal liver tissue and tumor,tumor and meta(if have).

  the day when conducting surgery (day 1)

Study Arms (1)

ICC patients

patients with intrahepatic cholangiocarcinoma treated by surgical treatment

Procedure: surgical treatment

Interventions

surgical treatment PROCEDURE

all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.

Also known as: hepatectomy

ICC patients

Eligibility Criteria

• Age: 16 Years - 90 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

intrahepatic cholangiocarcinoma patients underwent surgical therapy

You may qualify if:

• hepatocellular patients diagnosed through biopsy;or either dynamic imagine with a diagnosis of intrahepatic cholangiocarcinoma and CA199\>100U/L；or two or more dynamic imagine with a diagnosis of intrahepatic cholangiocarcinoma
• Child-Pugh A or B
• well preserved renal and hematopoietic Function
• receive complete surgical therapy
• achieve complete section accessed by contrast-enhanced CT

You may not qualify if:

• incomplete section
• Child-Pugh C
• combination with other hepatobiliary disease
• suffer from other tumors concurrently or in last five years

Sponsors & Collaborators

• First Affiliated Hospital, Sun Yat-Sen University: lead
• Guangdong Province, Department of Science and Technology: collaborator

Study Sites (1)

First Affiliated Hospital, Sun Yat-Sen University

Guangzhou, Guangdong, 510000, China

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Cut tissue into small pieces (\~2 mm2)and wash in drops of saline (1x PBS). Place pieces individually into LN2 in Styrofoam cup. Transfer pieces into LN2-cooled 1.5 mL cryovial. Pour out excess LN2 from vial, then seal and keep in LN2 until freezer storage.

MeSH Terms

Conditions

Cholangiocarcinoma; Cirrhosis, Familial, with Pulmonary Hypertension

Interventions

Surgical Procedures, Operative; Hepatectomy

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms

Intervention Hierarchy (Ancestors)

Digestive System Surgical Procedures

Study Officials

• Ming Kuang, MD

  First Affiliated Hospital, Sun Yat-Sen University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD,PhD

Study Record Dates

• First Submitted: August 5, 2013
• First Posted: August 6, 2013
• Study Start: October 1, 2012
• Primary Completion: December 1, 2013
• Study Completion: December 1, 2014
• Last Updated: August 6, 2013

Record last verified: 2013-08

Locations

CN (1)